Viridian Therapeutics, Inc.\DE (VRDN) Income towards Parent Company (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Income towards Parent Company history runs 14 years deep, the most recent figure standing at -$111.8 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 18.69% year-over-year to -$111.8 million; the TTM figure through Mar 2026 stood at -$357.8 million (down 5.95% YoY), while the FY2025 annual figure was -$652.8 million, down 37.16% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$111.8 million, down from -$99.3 million in the prior quarter.
• The five-year high for Income towards Parent Company was -$25.7 million in Q1 2022, with the low at -$111.8 million in Q1 2026.
• The 5-year median for Income towards Parent Company is -$68.2 million (2023), against an average of -$66.9 million.
• The sharpest annual moves came in 2023 and 2025: Income towards Parent Company tumbled 165.39% in 2023, then surged 61.69% in 2025.
• Viridian Therapeutics, Inc.\DE's Income towards Parent Company stood at -$45.6 million in 2022, then slumped by 84.56% to -$84.2 million in 2023, then advanced by 6.04% to -$79.1 million in 2024, then declined by 25.56% to -$99.3 million in 2025, then dropped by 12.54% to -$111.8 million in 2026.
• Business Quant data shows VRDN's Income towards Parent Company at -$111.8 million in Q1 2026, -$99.3 million in Q4 2025, and -$35.1 million in Q3 2025.